Role of antiangiogenic agents in the treatment of metastatic colorectal cancer

Contemporary data on different therapy schemes for colorectal cancer are presented from the point of view of “costeffectiveness” indicator. There is an information about Federal programs aimed at increasing annual healthcare financing connected with preventing and curing malignancies. The statistics of the annual growth in colon and rectum cancer rates is discussed. An actual problem of increasing number of resource-intensive medicines for oncology treatment is stated. This is the reason to analyze cost-effectiveness.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Role of antiangiogenic agents in the treatment of metastatic colorectal cancer

Abstract: О б з о р л и т е р а т у р ы

Cited by 2 publications

References 15 publications

Comprehensive treatment of rectal cancer patients with synchronous distant metastases

Comprehensive treatment of rectal cancer patients with synchronous distant metastases

Cost-effectiveness indicator for colorectal cancer therapy

Contact Info

Product

Resources

About